☆ 4.7 Article

Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis

JOURNAL OF GASTROENTEROLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Meeting Abstract Oncology

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA

Ghassan K. Abou-Alfa et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Hepatic Arterial Infusion of Oxaliplatin Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial

Qi-Jiong Li et al.

Summary: This study compared the overall survival of patients with unresectable large hepatocellular carcinoma treated with FOLFOX-HAIC or TACE as first-line therapy. The results showed that FOLFOX-HAIC significantly improved overall survival compared to TACE, with higher treatment response rate and longer progression-free survival.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1)

Ning Lyu et al.

Summary: In this phase III trial, hepatic arterial infusion chemotherapy (HAIC-FO) showed better survival outcomes than sorafenib in advanced hepatocellular carcinoma (HCC) patients. HAIC-FO responders had significantly improved prognosis compared to non-responders, and a gene prediction model was developed to predict response to HAIC-FO treatment.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Sorafenib Plus Hepatic ArterialInfusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized TriaL

Kanglian Zheng et al.

Summary: This study compared the efficacy and safety of sorafenib plus 3cir-OFF hepatic arterial infusion chemotherapy (HAIC) with sorafenib alone for advanced hepatocellular carcinoma (HCC) with major portal vein tumor thrombosis (PVTT). The results showed that sorafenib plus HAIC achieved better overall survival (OS) and longer progression-free survival (PFS) compared to sorafenib alone, but also had more adverse events.

RADIOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma

Grace L. Su et al.

Summary: This article presents the research and recommendations for systemic therapies for HCC, providing evidence-based guidelines for patients.

GASTROENTEROLOGY (2022)

添加到收藏夹

Review Oncology

Hepatocellular Carcinoma: Pick the Winner-Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent-Based Combinations

Anthony C. Bejjani et al.

Summary: The treatment landscape for advanced hepatocellular carcinoma has undergone significant changes in recent years, with the introduction of immunotherapy and the development of various treatment regimens. Some combination therapies have shown promising results in improving outcomes for patients. However, there are still knowledge gaps in this rapidly evolving field. It is important for clinicians to stay informed about the safety and efficacy of these evolving regimens to optimize patient outcomes.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

Maria Reig et al.

Summary: There have been significant advances in the treatment strategies for hepatocellular carcinoma since the last update in 2018. However, some interventions still lack sufficient data for clinical incorporation, and personalized clinical management requires consideration of multiple parameters.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Article Oncology

Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH)

Zhenwei Peng et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

R. S. Finn et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma

Jianfeng Guo et al.

Summary: This study demonstrates the concept of successful FOLFOX-associated CRC and HCC therapies through the combination of two nano delivery systems. Further optimization in dosing and timing has the potential to enhance the clinical efficacy of this combination strategy.

MOLECULAR CANCER (2021)

添加到收藏夹

Article Medicine, General & Internal

Hepatocellular carcinoma

Josep M. Llovet et al.

Summary: Liver cancer, particularly hepatocellular carcinoma (HCC), poses a significant global health challenge with rising incidence projected to exceed 1 million cases by 2025. Infection by hepatitis B and C viruses remains a major risk factor for HCC, while non-alcoholic steatohepatitis is emerging as a more common risk factor in Western countries. Advances in systemic therapies for HCC, including immunotherapies and targeted therapies, are expected to revolutionize the management of this disease.

NATURE REVIEWS DISEASE PRIMERS (2021)

添加到收藏夹

Article Oncology

Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma

Jingjun Huang et al.

Summary: In patients with large or huge HCC, D-TACE-HAIC resulted in higher ORR, longer PFS, and better OS compared to DEB-TACE. This was particularly evident in patients with non-smooth tumor margin or macrovascular invasion.

JOURNAL OF HEPATOCELLULAR CARCINOMA (2021)

添加到收藏夹

Review Oncology

Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update

Masatoshi Kudo et al.

Summary: The Clinical Practice Manual for Hepatocellular Carcinoma is based on evidence and expert consensus, focusing on pathology, diagnosis, and treatment. Different from the JSH Clinical Practice Guidelines, this manual emphasizes practicality and is written by a panel of experts from the JSH.

LIVER CANCER (2021)

添加到收藏夹

Review Oncology

Targeting the DNA damage response in immuno-oncology: developments and opportunities

Roman M. Chabanon et al.

Summary: Immunotherapy has greatly improved cancer treatment outcomes, but many patients still do not benefit from it, partly due to DDR deficiency. DDR-targeted therapies can enhance antitumor immune response by promoting antigenicity, enhancing adjuvanticity, and favoring reactogenicity.

NATURE REVIEWS CANCER (2021)

添加到收藏夹

Article Oncology

Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein

Yumi Kosaka et al.

Summary: The combination therapy of HAIC and RT shows promising results for advanced HCC patients with Vp4, significantly improving overall survival and progression-free survival rates. Factors such as >50% of relative tumor volume in the liver and extrahepatic spread have been identified as significant factors affecting overall survival.

LIVER CANCER (2021)

添加到收藏夹

Article Oncology

Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition)

Shuqun Cheng et al.

LIVER CANCER (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

mRECIST for HCC: Performance and novel refinements

Josep M. Llovet et al.

JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)

Jian Zhou et al.

LIVER CANCER (2020)

添加到收藏夹

Article Oncology

Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion A Randomized Clinical Trial

MinKe He et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study

Xubiao Wei et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Rational combinations of immunotherapy with radiotherapy in ovarian cancer

Fernando G. Herrera et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Review Gastroenterology & Hepatology

Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west

Jian Lu et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

AASLD guidelines for the treatment of hepatocellular carcinoma

Julie K. Heimbach et al.

HEPATOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma

Ning Lyu et al.

JOURNAL OF HEPATOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Peter R. Galle et al.

JOURNAL OF HEPATOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo et al.

LANCET (2018)

添加到收藏夹

Article Oncology

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

A. Vogel et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Freddie Bray et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2018)

添加到收藏夹

Review Oncology

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape

Leisha A. Emens et al.

EUROPEAN JOURNAL OF CANCER (2017)

添加到收藏夹

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

添加到收藏夹

Article Oncology

Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase

Junji Matsui et al.

CLINICAL CANCER RESEARCH (2008)

添加到收藏夹

Article Oncology

E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition

Junji Matsui et al.

INTERNATIONAL JOURNAL OF CANCER (2008)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.